Abstract:Diabetic peripheral neuropathy (DPN) refers to the development of peripheral nerve dysfunction in patients with diabetes when other causes are excluded. Diabetic distal symmetric polyneuropathy (DSPN) is the most representative form of DPN. As one of the most common complications of diabetes, its prevalence increases with the duration of diabetes. 10-15% of newly diagnosed T2DM patients have DSPN, and the prevalence can exceed 50% in patients with diabetes for more than 10 years. Bilateral limb pain, numbness, and paresthesia are the most common clinical manifestations in patients with DPN, and in severe cases, foot ulcers can occur, even leading to amputation. The etiology and pathogenesis of diabetic neuropathy are not yet completely clarified, but hyperglycemia, disorders of lipid metabolism, and abnormalities in insulin signaling pathways are currently considered to be the initiating factors for a range of pathophysiological changes in DPN. In the presence of abnormal metabolic factors, the normal structure and function of the entire peripheral nervous system are disrupted, including myelinated and unmyelinated nerve axons, perikaryon, neurovascular, and glial cells. In addition, abnormalities in the insulin signaling pathway will inhibit neural axon repair and promote apoptosis of damaged cells. Here, we will discuss recent advances in the study of DPN mechanisms, including oxidative stress pathways, mechanisms of microvascular damage, mechanisms of damage to insulin receptor signaling pathways, and other potential mechanisms associated with neuroinflammation, mitochondrial dysfunction, and cellular oxidative damage. Identifying the contributions from each pathway to neuropathy and the associations between them may help us to further explore more targeted screening and treatment interventions.

Relationship between Advanced Glycation End Products and Diabetic Peripheral Neuropathy

Advanced Glycation End Products:Novel Target for Treating Diabetic Nephropathy

AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.

Evaluation of the Impact of Advanced Glycation End-Products on Peripheral Neuropathy Outcomes in Type 2 Diabetes

Pathogenesis of Diabetic Peripheral Neuropathy and Prospect of Antioxidative Therapy

Inhibiting apoptosis of Schwann cell under the high-glucose condition: A promising approach to treat diabetic peripheral neuropathy using Chinese herbal medicine

Advanced Glycation End Products and Food

Advanced glycation end products in diabetic retinopathy and phytochemical therapy

Advanced Glycation End Products and Diabetic Vascular Complications

Advanced Glycation End-Products and Diabetic Neuropathy of the Retina

Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy

Accumulation of Advanced Glycation Endproducts and Subclinical Inflammation in Deep Tissues of Adult Patients with and Without Diabetes.

Effects of Mitochondrial Dysfunction via AMPK/PGC-1 α Signal Pathway on Pathogenic Mechanism of Diabetic Peripheral Neuropathy and the Protective Effects of Chinese Medicine

Electroacupuncture Alleviates Diabetic Peripheral Neuropathy by Regulating Glycolipid-Related GLO/AGEs/RAGE Axis

Advances in cardiovascular-related biomarkers to predict diabetic peripheral neuropathy

Synthesis of Advanced Glycation End Products and Their Relationship with Diseases

Diabetic Peripheral Neuropathy: Pathogenetic Mechanisms and Treatment

Correlation between skin advanced glycation end products and diabetic peripheral neuropath

Glycochelates and the etiology of diabetic peripheral neuropathy

Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets